Medical/Pharmaceuticals

China Biologic Special Committee Retains Financial Advisor and Legal Counsel

BEIJING, Oct. 17, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the special committee (the "Special Committee") of the Company's board o...

2019-10-17 20:00 714

Sirtex Medical appoints Kevin R. Smith as Chief Executive Officer

Interim CEO unanimously chosen to lead global operations in patient-first oncology innovation WOBURN, Mass., Oct. 16, 2019 /PRNewswire/ -- Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced the appointment ofKevin R. Smith as Chief Executive Officer of Sir...

2019-10-16 22:00 372

Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH

SHANGHAI, Oct. 16, 2019 /PRNewswire/ -- Hepagene Therapeutics, Inc, a clinical stage drug discovery and development company which devotes its efforts towards discovering, developing and delivering innovative medicines that help patients prevail over liver diseases, announced today that it has dos...

2019-10-16 18:00 164

CartiHeal Performs First Agili-C™ Cartilage Repair Implantation Procedure in Maryland

KFAR SABA, Israel, Oct. 15, 2019 /PRNewswire/ -- CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today the first implantation of the Agili-C™ implant, as part of Investigational Device Exemption (IDE) ...

2019-10-15 20:00 201

Collaborative Medicinal Development Enrolls First Patient In a Randomized, Placebo-Controlled Clinical Trial of CuATSM For The Treatment of Amyotrophic Lateral Sclerosis

MILL VALLEY, Calif. and MELBOURNE, Australia, Oct. 15, 2019 /PRNewswire/ -- Collaborative Medicinal Development, LLC) ("CMD"), a clinical stage biopharmaceutical company with a portfolio of candidates for treatment of neurological and neuropsychiatric diseases, announced today that it enrolled t...

2019-10-15 05:58 277

WONTECH Receives FDA Clearance for 'HairBoom Air'

SEOUL, South Korea, Oct. 14, 2019 /PRNewswire/ -- WONTECH (Reno Kim, CEO of WONTECH,www.wtlaser.com ) a leading Korean laser and energy based medical aesthetic device company announced that its LLLT hair loss treatment device, HairBoom Air, received U.S. Food and Drug Adm...

2019-10-14 16:47 239

STA To Market Sarcoma Drug In Australia, New Zealand And SE Asia Following License Deal

SINGAPORE and MELBOURNE, Australia, Oct. 14, 2019 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed a new license deal, enabling it to provide a global advanced sarcoma therapy to patients inAustralia, New Zealand and throughout SE Asia. Under the ...

2019-10-14 14:00 241

Kangpu Biopharmaceuticals Successfully Completed Phase I Study of Novel CRL4-CRBN Modulator KPG-818 in the U.S.

SHANGHAI, Oct. 11, 2019 /PRNewswire/ -- Kangpu Biopharmaceuticals announced today that it has successfully completed a first-in-human phase I single ascending dose (SAD) clinical study of KPG-818 conducted inthe United States. This randomized, double-blind, placebo-controlled study evaluated the...

2019-10-11 13:00 296

WuXi AppTec Research Service Division and BioSolveIT Introduce GalaXi®, a Vast New Chemical Space of Tangible Molecules

SHANGHAI and CAMBRIDGE, Massachusetts and SANKT AUGUSTIN, Germany, Oct. 10, 2019 /PRNewswire/ -- WuXi AppTec Research Service Division and BioSolveIT today launched a new virtual chemical space called GalaXi®. Largely built from WuXi AppTec's library of novel drug-like scaffolds, GalaXi® offers a...

2019-10-11 08:02 5858

I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5

SHANGHAI, Oct. 4, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases, today announced that its I...

2019-10-04 13:40 449

Medicago's New Drug Submission accepted for scientific review by Health Canada: An important step for Medicago towards commercialization of its innovative influenza vaccine

QUEBEC CITY, Oct. 3, 2019 /PRNewswire/ -- Medicago, a biotechnology company and global leader in the development and production of plant-derived vaccines with headquarters inQuebec City, announces today that Health Canada accepted for scientific review its New Drug Submission (NDS) for a plant-ba...

2019-10-03 06:30 378

Mayne Pharma Signs 20-Year Exclusive License and Supply Agreement for Novel Oral Contraceptive in the US

ADELAIDE, Australia, Oct. 2, 2019 * Mayne Pharma Group Limited (Mayne Pharma or Company) (ASX: MYX) has signed a 20‑year exclusive supply and license agreement with Mithra Pharmaceuticals, SA (Mithra) to commercialise a novel oral contraceptive comprising Estetrol (E4), and drospirenone, (E4/...

2019-10-02 12:01 7518

Shanghai Pharma Global Standard Stock Incentive Scheme to Push Innovation Refiled for Approval

SHANGHAI, Sept. 30, 2019 /PRNewswire/ -- Shanghai Pharmaceuticals Holding Co., Ltd. (Shanghai Pharma) (Hong Kong Stock Exchange: 2607) (Shanghai Stock Exchange: 601607) has launched a new stock incentive plan (the Plan) aligned with international standards aimed at retaining and attracting talent...

2019-10-01 04:00 7014

Ascletis Announces Departure of Chief Financial Officer

HANGZHOU and SHAOXING, China, Sept. 30, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces that Dr.Lindi Tan, Chi...

2019-09-30 16:30 241

Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 (an Oral EP4 Antagonist) for Locally Advanced Rectal Cancer at ESMO 2019

NORTH BRUNSWICK, New Jersey, Sept. 30, 2019 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye" or "the Company"), a global clinical-stage biopharmaceutical company dedicated to discovery, development and commercialization of new and effective drugs with a focus on Oncology, announced today at the ...

2019-09-30 13:41 213

The 10th China (Taizhou) International Medical Expo successfully ended

NANJING, China, Sept. 30, 2019 /PRNewswire/ -- From September 18 to 20, the 10th China (Taizhou) International Medical Expo was held in China Medical City (CMS), according toChina (Taizhou) Medical Expo News Center.

2019-09-30 13:27 247

Bridge Biotherapeutics Presents Positive Results from Phase 1 Clinical Study of BBT-877 for Idiopathic Pulmonary Fibrosis (IPF) Treatments at the ERS International Congress 2019

* The study results presented at the ERS 2019 as a late breaking abstract demonstrated positive safety and tolerance in healthy volunteers * Data demonstrated LPA inhibition of BBT-877 up to 90% in multiple-ascending dose cohorts SEONGNAM, South Korea and MADRID, Sept. 29, 2019 /PRNewswire/ --...

2019-09-30 06:00 293

Kinoxis Therapeutics Awarded NIH HEAL Initiative Grant to Advance KNX100 for the Treatment of Opioid Withdrawal

MELBOURNE, Australia and SYDNEY, Sept. 29, 2019 /PRNewswire/ -- Kinoxis Therapeutics Pty Ltd, a pre-clinical stage biotechnology company developing novel therapies for substance use disorders and other central nervous system disorders, has been awarded a major grant from the US National Institut...

2019-09-30 05:00 276

CYZone announced "The 2019 Top 50 Healthcare Innovation Enterprises" in China

HANGZHOU, China, Sept. 26, 2019 /PRNewswire/ -- CYZone (www.cyzone.cn ), a leading innovation service platform in China, recently announced "The 2019 Top 50 Healthcare Innovation Enterprises inChina" on Demo China FutureTech Festival. There are 50 prominent companies on th...

2019-09-26 21:36 608

Preclincal Results of Baoyuan's Next-Generation ROS1/NTRK Inhibitor AB-106 Published in Nature Communications

HANGZHOU, China, Sept. 25, 2019 /PRNewswire/ -- The preclinical results of AB-106 (original code: DS-6051b), an investigational next generation ROS1/NTRK dual inhibitor exclusively in-licensed by AnHeart Therapeutics, a wholly-owned subsidiary of Baoyuan Biopharmaceuticals Technology (Hangzhou) C...

2019-09-25 18:35 727
12345 ... 219